King Cuts Workforce By 20% In Wake Of Altace Decision
This article was originally published in The Pink Sheet Daily
Executive Summary
Size and focus of sales force will be restructured, King says.
You may also be interested in...
King Looks To Reign Over Pain With Acura Deal
Deal covers development and commercialization of four immediate-release opioid analgesics, including Acurox tablets for acute pain.
King Looks To Reign Over Pain With Acura Deal
Deal covers development and commercialization of four immediate-release opioid analgesics, including Acurox tablets for acute pain.
King/Palatin Put Phase III Plans For Erectile Dysfunction Product On Hold
Risk/benefit profile for bremelanotide unacceptable for first-line use, but compound may have value as second-line therapy for PDE-5 nonresponders, FDA says.